Signaling roles of platelets in skeletal muscle regeneration

Graca, Flavia A.; Minden‐Birkenmaier, Benjamin A.; Stephan, Anna; Demontis, Fabio; Labelle, Myriam

doi:10.1002/bies.202300134

Cited by 5 publications

(2 citation statements)

References 49 publications

(134 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors evidenced improper platelet activation in patients may be associated with muscle fatigue. In fact, platelet‐derived signalling factors are instrumental in guiding tissue regeneration, a process activated in the skeletal muscle after exercise 121 …”

Section: Pathophysiological Mechanismsmentioning

confidence: 99%

Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances

Pietrangelo,

Cagnin,

Bondi

et al. 2024

Acta Physiologica

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a demanding medical condition for patients and society. It has raised much more public awareness after the COVID‐19 pandemic since ME/CFS and long‐COVID patients share many clinical symptoms such as debilitating chronic fatigue. However, unlike long COVID, the etiopathology of ME/CFS remains a mystery despite several decades' research. This review moves from pathophysiology of ME/CFS through the compelling evidence and most interesting hypotheses. It focuses on the pathophysiology of skeletal muscle by proposing the hypothesis that skeletal muscle tissue offers novel opportunities for diagnosis and treatment of this syndrome and that new evidence can help resolve the long‐standing debate on terminology.

show abstract

Section: Pathophysiological Mechanismsmentioning

confidence: 99%

Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances

Pietrangelo,

Cagnin,

Bondi

et al. 2024

Acta Physiologica

View full text Add to dashboard Cite

show abstract

“…Muscle regeneration relies on the microenvironment surrounding satellite cells in the individual damaged muscle fascicle, as well as the macroenvironment perpetuated by the inflammatory cascade initiated from the primary insult to the muscle (25,26). The signaling role that platelets play in this process has made autologous blood product a potentially enticing treatment for these injuries (27). PRP has been studied extensively in cellular and animal models to determine the impact of the product on muscle regeneration.…”

Section: Basic Science/preclinical Datamentioning

confidence: 99%

Platelet-Poor versus Platelet-Rich Plasma for the Treatment of Muscle Injuries

Raum,

Kenyon,

Bowers

2024

Curr Sports Med Rep

View full text Add to dashboard Cite

Muscle injury in sport results in significant lost time and potential for reinjury for athletes. Autologous blood product, namely, platelet-rich plasma (PRP), has been investigated for possible augmentation of the treatment timeline with prevention of reinjury; however, conflicting results have been identified. A growing body of basic science and clinical literature is forming that supports the use of platelet-poor plasma (PPP) for muscle injury. The purpose of this study was to provide a background of the basic science of PRP versus PPP for muscle injury and to identify and review the clinical evidence for both autologous blood products, including the author’s clinical experience utilizing the blood products. At the tissue level, PRP causes myoblast proliferation while PPP has led to myoblast induction, potentially identifying improved native muscle healing. Conflicting studies have been identified for the use of PRP for muscle injury. A growing body of positive results for PPP was identified, but high-quality comparative studies are needed.

show abstract

Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia

Aparicio,

Navarrete‐Villanueva,

Gómez‐Cabello

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundSarcopenia, the gradual and generalized loss of muscle mass and function with ageing, is one of the major health problems in older adults, given its high prevalence and substantial socioeconomic implications. Despite the extensive efforts to reach consensus on definition and diagnostic tests and cut‐offs for sarcopenia, there is an urgent and unmet need for non‐invasive, specific and sensitive biomarkers for the disease. Extracellular vesicles (EVs) are present in different biofluids including plasma, whose cargo reflects cellular physiology. This work analysed EV proteome in sarcopenia and robust patients in the search for differentially contained proteins that can be used to diagnose the disease.MethodsPlasma small EVs (sEVs) from a total of 29 robust controls (aged 73.4 ± 5.6 years; 11 men and 18 women) and 49 sarcopenic patients (aged 82.3 ± 5.4 years; 15 men and 34 women) aged 65 years and older were isolated and their cargo was analysed by proteomics. Proteins whose concentration in sEVs was different between sarcopenic and robust patients were further validated using ELISA. The concentration of these candidates was correlated to the EWGSOP2 sarcopenia tests for low muscle strength and low physical performance, and receiver operating characteristic (ROC) curve analyses were carried out to evaluate their diagnostic power, sensitivity and specificity.ResultsProteomic analysis identified 157 sEVs proteins in both sarcopenic and robust samples. Among them, 48 proteins had never been reported in the ExoCarta nor Vesiclepedia databases. Statistical analysis revealed eight proteins whose concentration was significantly different between groups: PF4 (log2 FC = 4.806), OIT3 (log2 FC = −1.161), MMRN1 (log2 FC = −1.982), MASP1 (log2 FC = −0.627), C1R (log2 FC = 1.830), SVEP1 (log2 FC = 1.295), VCAN (FC = 0.937) and SPTB (log2 FC = 1.243). Among them, platelet factor 4 (PF4) showed the lowest concentration while Complement C1r subcomponent (C1R) increased the most in sarcopenic patients, being these results confirmed by ELISA (P = 1.07E‐09 and P = 0.001287, respectively). The concentrations of candidate proteins significantly correlated with EWGSOP2 tests currently used. ROC curve analysis showed an area under the curve of 0.8921 and 0.7476 for PF4 and C1R, respectively. Choosing the optimal for PF4, 80% sensitivity and 85.71% specificity was reached while the optimal cut‐off value of C1R would allow sarcopenia diagnosis with 75% sensitivity and 66.67% specificity.ConclusionsOur results support the determination of EV PF4 and C1R as plasma diagnostic biomarkers in sarcopenia and open the door to investigate the role of the content of these vesicles in the pathogeny of the disease.

show abstract

Signaling roles of platelets in skeletal muscle regeneration

Cited by 5 publications

References 49 publications

Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances

Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances

Platelet-Poor versus Platelet-Rich Plasma for the Treatment of Muscle Injuries

Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia

Contact Info

Product

Resources

About